Managed Healthcare Executive

Coramitug wins FDA fast track status for rare heart condition

Coramitug is designed to clear toxic protein deposits from the heart, offering a new approach to treating ATTR cardiomyopathy ...
MPR

FDA Fast-Tracks Coramitug, an Antibody-Depleting Therapy for ATTR-CM

Coramitug is currently being investigated in the phase 3 CLEOPATTRA trial in approximately 1280 patients with ATTR-CM.

Scancell wins FDA fast-track status for melanoma immunotherapy

The AIM-listed biotech reports 77% progression-free survival at 20 months, well ahead of the standard of care Scancell ...

Prothena announces Novo Nordisk obtains fast track designation from the US FDA for Coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase 3 ...
MPR

FDA Fast Tracks Intra-Articular GLP-1RA for Knee Osteoarthritis

By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.

FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)’s KT-621 for Eosinophilic Asthma

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Kymera Therapeutics, Inc. is among the ...